OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer ...
Whichever side of an issue you’re on, it’s likely that at the root of what gets you fired up are deep, fundamental human ...
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted ...
Former firefighter John Knox's ties to RFK Jr. have landed him atop the agency that helped bring Covid-19 under control.
Leaders in Durham are sounding the alarm about political rhetoric they believe could incite violence. Social media posts have ...
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseasesCAMBRIDGE, Mass., (GLOBE ...
The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...
An anonymous $1 million gift to the Center for Communication Research will expand research, professional development and experiential learning opportunities.
The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...
The University of Arkansas community is invited to celebrate the service and contributions of Lori McLemore, assistant director of marketing and recruitment for the Graduate School of Business in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback